TY - JOUR T1 - R1441G but not G201S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils JF - medRxiv DO - 10.1101/2021.01.28.21249614 SP - 2021.01.28.21249614 AU - Ying Fan AU - Raja S. Nirujogi AU - Alicia Garrido AU - Javier Ruiz Martínez AU - Alberto Bergareche-Yarza AU - Elisabet Mondragón Rezola AU - Ana Vinagre Aragón AU - Ioana Croitoru AU - Ana Gorostidi Pagola AU - Laura Paternain Markinez AU - Roy Alcalay AU - Richard A. Hickman AU - Jonas Duering AU - Neringa Pratuseviciute AU - Shalini Padmanabhana AU - Francesc Valldeoriola AU - Maria José Martí AU - Eduardo Tolosa AU - Dario R Alessi AU - Esther Sammler Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/31/2021.01.28.21249614.abstract N2 - Gain-of kinase function variants in LRRK2 (leucine-rich repeat kinase 2) cause Parkinson’s disease (PD), albeit with incomplete and age-dependent penetrance, offering the prospect of disease-modifying treatment strategies via LRRK2 kinase inhibition. LRRK2 phosphorylates a subgroup of RabGTPases including Rab10 and pathogenic mutations enhance LRRK2-mediated phosphorylation of Rab10 at Thr73.In this study we analyse LRRK2 dependent Rab10Thr73 phosphorylation in human peripheral blood neutrophils isolated from 101 individuals using quantitative immunoblotting and mass spectrometry. Our cohort includes 42 LRRK2 mutation carriers (21 with the G2019S mutation that resides in the kinase domain and 21 with the R1441G mutation that lies within the ROC-COR domain), 27 patients with idiopathic PD, and 32 controls.We show that LRRK2 dependent Rab10 Thr73 phosphorylation is significantly elevated in all R1441G LRRKR2 mutation carriers irrespective of disease status. PD manifesting and non-manifesting G2019S mutation carriers as well as idiopathic PD samples did not display elevated Rab10 Thr73 phosphorylation. Furthermore, we analysed brain samples of 10 G2019S and 1 R1441H mutation carriers as well as 10 individuals with idiopathic PD and 10 controls. We find high variability for pRab10Thr73 phosphorylation amongst donors irrespective of genetic and disease state.We conclude that in vivo LRRK2 dependent pRab10Thr73 analysis in human peripheral blood neutrophils is a specific and robust biomarker for LRRK2 kinase activation for individuals with mutations such as R1441G that enhance pRab10Thr73 phosphorylation over 2-fold. We provide the first evidence that the LRRK2 R1441G mutation enhances LRRK2 kinase activity in a primary human cell.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialnot applicableFunding StatementThe work was supported by funding from the Michael J. Fox Foundation for Parkinson's Research, small grant funding from Parkinsons UK, and Medical Research Councile (Dario Alessi). Esther Sammler was supported by the Tayside medical Science Centre (TASC) and a Scottish Senior Clinical Academic Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by the respective Institutional Review Boards at the University Hospital in Barcelona and Biodonostia Health Research Institute in San Sebastian, Spain and the University of Columbia in New York, US. Tissue and lysates were stored and used at the University of Dundee in line with regulations from the Tayside Tissue bank. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available ER -